Marker Therapeutics was awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas to support its lead MAR-T therapy, MT-601, in the planned Phase 2 APOLLO study.
MRKR · Marker Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 36%
- Last earnings
- Nov 10, 2021
- Latest filing
- 10-Q · Nov 16
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Marker Therapeutics' nine-month net loss narrowed to $6.8 million from $10.5 million, as research and development expenses fell 33%. The company cites substantial doubt about going concern and anticipates funding operations into the second quarter of 2027.
Marker Therapeutics was awarded $2.6 million by the FDA to fund a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer. Clinical initiation is anticipated in the first quarter of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRKR
this stock
Marker Therapeutics, Inc.
|
$18.17M | -26.8% | -100.0% | — | 1.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 13
Marker Therapeutics was awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas to support its lead MAR-T therapy, MT-601, in the planned Phase 2 APOLLO study.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRKR | +25.3% | +13.5% | -23.2% | +11.2% | -26.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +33.9% | +22.8% | -14.1% | +19.9% | -28.0% |